Stock Quotes & Company News | Reuters.com
Edition:
United States

People: Omeros Corp (OMER.OQ)

OMER.OQ on NASDAQ Stock Exchange Global Market

10.24USD
28 Jun 2016
Change (% chg)

-- (--)
Prev Close
$10.24
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
116,399
52-wk High
$30.21
52-wk Low
$8.90

Demopulos, Gregory 

Dr. Gregory A. Demopulos, M.D., is Chairman of the Board, President, Chief Executive Officer of Omeros Corp. Gregory A. Demopulos, M.D., founded our company and has served as our president, chief executive officer and chairman of the board of directors since June 1994. In an interim capacity, he also served as our chief financial officer and treasurer from January 2009 to October 2013 and as our chief medical officer from June 1994 to March 2010. Prior to founding Omeros, Dr. Demopulos completed his residency in orthopedic surgery at Stanford University and his fellowship training in hand and microvascular surgery at Duke University. Dr. Demopulos currently serves on the board of trustees of the Smead Funds Trust, an open-end mutual fund company registered under the Investment Company Act of 1940, and on the board of directors of Onconome, Inc., a privately held company developing biomarkers for early cancer detection. His non-profit service includes the Seattle Community Development Round Table and the Northwest NeuroNeighborhood board of directors. Dr. Demopulos received his M.D. from the Stanford University School of Medicine and his B.S. from Stanford University. Our nominating and governance committee has concluded that Dr. Demopulos should continue to serve on the board of directors based on his position and experience as our chief executive officer and his medical and scientific expertise, experience with clinical development and design and knowledge of our operations and development programs. Dr. Demopulos is the brother of Peter A. Demopulos, M.D., a member of our board of directors.

Basic Compensation

Total Annual Compensation, USD 684,125
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 3,253,910
Fiscal Year Total, USD 3,938,040

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised 10,000 103,100.00